Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2017-06-22FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan Hycela (rituximab and hyaluronidase) by Genentech, updating the labeling for this subcut…
-
CLINICAL_TRIALS trial_result · 2017-06-02Clinical Trial Update: Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma [Phase 1, Phase 2]
Clinical trial update reports completed Phase 1 and Phase 2 results for flavopiridol in previously treated chronic lymphocytic leukemia and …
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL [Phase 2]
Phase 2 trial of idelalisib plus rituximab in elderly patients with untreated CLL or SLL; study terminated with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2017-05-19Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]
The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS trial_result · 2017-05-18Clinical Trial Update: Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial evaluating idelalisib plus rituximab for previously untreated follicular lymphoma and small lymphocytic lymphoma was terminate…
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies [Phase 2, Phase 3]
A phase 2/3 trial evaluating non-myeloablative allogeneic HSCT from HLA-matched related or unrelated donors in low-grade B-cell malignancies…
-
CLINICAL_TRIALS trial_result · 2017-05-03Clinical Trial Update: Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial evaluating donor stem cell transplantation for high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia [Phase 1]
A Phase I dose-escalation study of CAT-8015 (moxetumomab pasudotox) in participants with chronic leukemia; the trial was terminated and resu…
-
CLINICAL_TRIALS withdrawal · 2017-04-05Clinical Trial Update: Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation [Phase 2]
This clinical trial update reports that the Phase 2 study of Sotrastaurin acetate for relapsed or refractory chronic lymphocytic leukemia, s…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant [Phase 2]
Phase 2 study evaluating lenalidomide with or without rituximab in patients with relapsed or progressive chronic lymphocytic leukemia, small…
-
CLINICAL_TRIALS trial_result · 2017-03-20Clinical Trial Update: Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL [Phase 2]
A Phase 2 trial evaluating dasatinib in combination with fludarabine and rituximab in relapsed or refractory chronic lymphocytic leukemia an…
-
CLINICAL_TRIALS trial_result · 2017-03-17Clinical Trial Update: Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma [Phase 2]
A Phase 2 study evaluating ofatumumab as initial systemic therapy for indolent B-cell lymphomas has completed, with results posted in March …
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Tandem Auto-Allo Transplant for Lymphoma [Phase 2]
Phase 2 clinical trial update on tandem auto-allo transplantation for various lymphomas, with completed status and results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma [Phase 3]
Phase 3 trial comparing ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma com…
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of fludarabine, rituximab, and alemtuzumab in patients with chronic lymphocytic leukemia or small…
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1, Phase 2]
This document provides an update on a Phase 1/2 clinical trial evaluating the combination of etanercept and rituximab in patients with chron…
-
FDA approval · 2017-02-06FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) submitted by Teva Pharmaceuticals USA, Inc., reflecting an …
-
CLINICAL_TRIALS trial_result · 2016-12-21Clinical Trial Update: Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma [Phase 1, Phase 2]
Clinical trial update for idelalisib (GS-1101) in previously treated indolent non-Hodgkin's lymphoma, including follicular lymphoma, reporti…
-
CLINICAL_TRIALS trial_result · 2016-12-12Clinical Trial Update: Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus with alemtuzumab in recurrent chronic lymphocytic leukemia or small lymphocytic lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2016-10-06Clinical Trial Update: A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma [Phase 1]
Phase 1 study evaluating TRU-016 in combination with Rituximab and Bendamustine in relapsed indolent B-cell lymphoma; results posted in 2016…
-
FDA approval · 2016-09-21FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) filed by Gilead Sciences, Inc.
-
CLINICAL_TRIALS withdrawal · 2016-07-26Clinical Trial Update: A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor [Phase 1]
A Phase 1 study of the combination of duvelisib and venetoclax in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lym…